Stock CALC CALCIMEDICA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CalciMedica, Inc. OTC Markets

Equities

CALC

US38942Q2021

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 16:30:01 2024-07-16 EDT 		5-day change 1st Jan Change
4.88 USD +1.46% Intraday chart for CalciMedica, Inc. +13.18% +68.18%
07-10 Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained MT
07-09 CalciMedica Says First Person Dosed in Phase 2 Trial of Auxora to Treat Acute Kidney Injury MT

Valuation

Fiscal Period: Dezember 2023 2024 2025 2026
Capitalization 1 16.26 51.7 - -
Enterprise Value (EV) 1 16.26 51.7 51.7 51.7
P/E ratio -0.37 x -3.12 x -3.13 x -3.5 x
Yield - - - -
Capitalization / Revenue - - - 18.5 x
EV / Revenue - - - 18.5 x
EV / EBITDA -0.43 x -2.17 x -1.8 x -1.83 x
EV / FCF - -1.67 x -1.48 x -1.2 x
FCF Yield - -60% -67.7% -83.2%
Price to Book - - - -
Nbr of stocks (in thousands) 5,685 10,749 - -
Reference price 2 2.860 4.880 4.880 4.880
Announcement Date 24-03-28 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Dezember 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 2.8
EBITDA 1 - - -38.02 -23.8 -28.7 -28.2
EBIT 1 - - -38.08 -23.77 -29.23 -32.6
Operating Margin - - - - - -1,164.29%
Earnings before Tax (EBT) 1 - - -34.36 -18.53 -27.87 -32.45
Net income 1 -23.5 -14.51 -34.36 -18.53 -27.87 -32.45
Net margin - - - - - -1,158.93%
EPS 2 -8.650 -5.080 -7.660 -1.563 -1.557 -1.395
Free Cash Flow 1 - - - -31 -35 -43
FCF margin - - - - - -1,535.71%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 23-01-20 23-04-04 24-03-28 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - -
EBITDA 1 - - - -4.3 -5.752 -5.5 -6.7 -5.9
EBIT 1 -22.34 -6.583 -4.833 -4.319 -5.767 -6.35 -5.4 -5.6
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 -19.29 -6.304 -4.619 -4.146 0.13 -5.733 -6.533 -6.367
Net income 1 -19.29 -6.304 -4.619 -4.146 0.13 -5.733 -6.533 -6.367
Net margin - - - - - - - -
EPS 2 -3.407 -1.110 -0.8200 -0.2300 0.0100 -0.5267 -0.5800 -0.4167
Dividend per Share - - - - - - - -
Announcement Date 23-05-12 23-08-10 23-11-09 24-03-28 24-05-13 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - - -31 -35 -43
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 - - - - - -
Capex / Sales - - - - - -
Announcement Date 23-01-20 23-04-04 24-03-28 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.88 USD
Average target price
18.33 USD
Spread / Average Target
+275.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.17% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+24.67% 117B
ARGENX SE Stock argenx SE
+25.44% 27.67B
BIONTECH SE Stock BioNTech SE
-17.74% 20.33B
GENMAB A/S Stock Genmab A/S
-15.17% 16.79B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.21% 15.63B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.91% 14.84B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.10% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+54.50% 14.43B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CALC Stock
  4. CALC Stock
  5. Financials CalciMedica, Inc.